With populations aging, chronic diseases becoming more prevalent, and global health experts warning of potential pandemics, the need for rapid therapeutic development has reached unprecedented levels.

Innovation in ophthalmology is often measured by what reaches the clinic—but the path to those breakthroughs begins much ...

In today’s ultra-competitive global marketplace, life sciences companies are continually seeking ways to improve their research effectiveness and efficiency. Increasingly, real-world data (RWD) is ...

Over the past few years, we’ve seen a wave of digital innovation in clinical trials: decentralized models, eConsent, real-time monitoring and direct-to-patient logistics. We’ve digitized nearly every ...

A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...

Despite rapid growth, only 9.2% of DCTs are multiregional and over 80% single-country, indicating challenges in international implementation. 2 With regulatory agencies 4–7 underscoring risk-based ...

A newly released independent research review is contributing fresh scientific perspective to the ongoing discussion around ...

As we step into 2026, the AI and analytics story for health care and life sciences isn't about sudden disruption -- it's about a steady, strategic evolution toward smart, practical innovation. The ...

My thesis initiates coverage of big pharma stock AstraZeneca, with an initial buy rating, agreeing with today's bullish consensus. Positive upside is driven by the diverse portfolio of solutions to ...

In my followup on Takeda Pharmaceutical Co (TAK), I am reaffirming my buy rating from March. Clinical demand in multiple areas, along with an active drug pipeline, could keep driving the top-line ...

For the first time in Korea, Hallym University Medical Center (Director Kim Yong-sun) has obtained the highest grade ...